Skip to main content

Acute Low Back Pain

1
Pipeline Programs
5
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Daewon Pharma
Daewon PharmaKorea - Hwaseong
1 program
1
DW340Phase 21 trial
Active Trials
NCT03424707Completed45Est. Aug 2016
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
nicoboxilPHASE_31 trial
Active Trials
NCT01708915Completed805Est. Apr 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boehringer Ingelheimnicoboxil
Daewon PharmaDW340

Clinical Trials (2)

Total enrollment: 850 patients across 2 trials

Nonivamide/Nicoboxil Ointment in Acute Low Back Pain

Start: Oct 2012Est. completion: Apr 2013805 patients
Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back Pain

Start: Mar 2016Est. completion: Aug 201645 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.